Experience of advate rahf-pfm in previously untreated patients and minimally treated patients with haemophilia a

Guenter Auerswald, Alexis A. Thompson, Michael Recht, Deborah Brown, Raina Liesner, Norma Guzmán-Becerra, Jacqueline Dyck-Jones, Bruce Ewenstein, Brigitt Abbuehl

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We report a prospective trial of 55 previously untreated patients (PUPs) and minimally treated patients (MTPs) with severe/moderately severe haemophilia A (baseline factor VIII [FVIII] ≤2%) treated with a single FVIII replacement product. It was the objective of this study to evaluate the immunogenicity, efficacy, and safety of rAHF-PFM (Advate ®). On-demand or prophylactic treatment regimens were determined at the discretion of the investigator. rAHF-PFM was also permitted for peri-operative management. There were 633 bleeding episodes (BEs), including 517 treated, and 466 rated for efficacy. Haemostatic efficacy was considered excellent/good in 93% of 466 rated treatments. Of 517 treated BEs, 463/517 (90%) were managed with one (356/517 [69%]) or two infusions (107/517 [21%]). There were 27 surgeries. Intraoper-ative (n=22) and postoperative (n=25) haemostatic efficacies were considered excellent or good in 100% of rated surgeries. Related serious adverse events (SAEs) were inhibitor development in 16/55 (29.1%) subjects who received at least one infusion of rAHF-PFM. Non-serious, related adverse events (AEs) were few in number (14 in eight subjects). The odds ratio (OR [95% Confidence Interval, CI]) of developing inhibitors was significantly higher in subjects with a family history of inhibitor (4.95 [1.29-19.06]), non-Caucasian ethnicity (4.18, [1.18-14.82]), and intensive treatment at high dose (4.5 [1.05-19.25]) within ≤20 exposure days (EDs). In conclusion, rAHF-PFM was safe and effective for the management and perioperative coverage of PUPs/ MTPs with severe/moderately severe haemophilia A. This report supports previous findings from studies in which family history of inhibitor, non-Caucasian ethnicity, and high intensity treatment were associated with high risk of inhibitor development.

Original languageEnglish (US)
Pages (from-to)1072-1082
Number of pages11
JournalThrombosis and Haemostasis
Volume107
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Hemophilia A
Factor VIII
Hemostatics
Hemorrhage
Therapeutics
Odds Ratio
Research Personnel
Confidence Intervals
Safety

Keywords

  • Factor viii
  • Factor viii inhibitor
  • Haemophilia a
  • Minimally treated patients
  • Paediatric
  • Previously untreated patients

ASJC Scopus subject areas

  • Hematology

Cite this

Auerswald, G., Thompson, A. A., Recht, M., Brown, D., Liesner, R., Guzmán-Becerra, N., ... Abbuehl, B. (2012). Experience of advate rahf-pfm in previously untreated patients and minimally treated patients with haemophilia a. Thrombosis and Haemostasis, 107(6), 1072-1082. https://doi.org/10.1160/TH11-09-0642

Experience of advate rahf-pfm in previously untreated patients and minimally treated patients with haemophilia a. / Auerswald, Guenter; Thompson, Alexis A.; Recht, Michael; Brown, Deborah; Liesner, Raina; Guzmán-Becerra, Norma; Dyck-Jones, Jacqueline; Ewenstein, Bruce; Abbuehl, Brigitt.

In: Thrombosis and Haemostasis, Vol. 107, No. 6, 06.2012, p. 1072-1082.

Research output: Contribution to journalArticle

Auerswald, G, Thompson, AA, Recht, M, Brown, D, Liesner, R, Guzmán-Becerra, N, Dyck-Jones, J, Ewenstein, B & Abbuehl, B 2012, 'Experience of advate rahf-pfm in previously untreated patients and minimally treated patients with haemophilia a', Thrombosis and Haemostasis, vol. 107, no. 6, pp. 1072-1082. https://doi.org/10.1160/TH11-09-0642
Auerswald, Guenter ; Thompson, Alexis A. ; Recht, Michael ; Brown, Deborah ; Liesner, Raina ; Guzmán-Becerra, Norma ; Dyck-Jones, Jacqueline ; Ewenstein, Bruce ; Abbuehl, Brigitt. / Experience of advate rahf-pfm in previously untreated patients and minimally treated patients with haemophilia a. In: Thrombosis and Haemostasis. 2012 ; Vol. 107, No. 6. pp. 1072-1082.
@article{58fb7e165b314c49ab0bd413658bf633,
title = "Experience of advate rahf-pfm in previously untreated patients and minimally treated patients with haemophilia a",
abstract = "We report a prospective trial of 55 previously untreated patients (PUPs) and minimally treated patients (MTPs) with severe/moderately severe haemophilia A (baseline factor VIII [FVIII] ≤2{\%}) treated with a single FVIII replacement product. It was the objective of this study to evaluate the immunogenicity, efficacy, and safety of rAHF-PFM (Advate {\circledR}). On-demand or prophylactic treatment regimens were determined at the discretion of the investigator. rAHF-PFM was also permitted for peri-operative management. There were 633 bleeding episodes (BEs), including 517 treated, and 466 rated for efficacy. Haemostatic efficacy was considered excellent/good in 93{\%} of 466 rated treatments. Of 517 treated BEs, 463/517 (90{\%}) were managed with one (356/517 [69{\%}]) or two infusions (107/517 [21{\%}]). There were 27 surgeries. Intraoper-ative (n=22) and postoperative (n=25) haemostatic efficacies were considered excellent or good in 100{\%} of rated surgeries. Related serious adverse events (SAEs) were inhibitor development in 16/55 (29.1{\%}) subjects who received at least one infusion of rAHF-PFM. Non-serious, related adverse events (AEs) were few in number (14 in eight subjects). The odds ratio (OR [95{\%} Confidence Interval, CI]) of developing inhibitors was significantly higher in subjects with a family history of inhibitor (4.95 [1.29-19.06]), non-Caucasian ethnicity (4.18, [1.18-14.82]), and intensive treatment at high dose (4.5 [1.05-19.25]) within ≤20 exposure days (EDs). In conclusion, rAHF-PFM was safe and effective for the management and perioperative coverage of PUPs/ MTPs with severe/moderately severe haemophilia A. This report supports previous findings from studies in which family history of inhibitor, non-Caucasian ethnicity, and high intensity treatment were associated with high risk of inhibitor development.",
keywords = "Factor viii, Factor viii inhibitor, Haemophilia a, Minimally treated patients, Paediatric, Previously untreated patients",
author = "Guenter Auerswald and Thompson, {Alexis A.} and Michael Recht and Deborah Brown and Raina Liesner and Norma Guzm{\'a}n-Becerra and Jacqueline Dyck-Jones and Bruce Ewenstein and Brigitt Abbuehl",
year = "2012",
month = "6",
doi = "10.1160/TH11-09-0642",
language = "English (US)",
volume = "107",
pages = "1072--1082",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "6",

}

TY - JOUR

T1 - Experience of advate rahf-pfm in previously untreated patients and minimally treated patients with haemophilia a

AU - Auerswald, Guenter

AU - Thompson, Alexis A.

AU - Recht, Michael

AU - Brown, Deborah

AU - Liesner, Raina

AU - Guzmán-Becerra, Norma

AU - Dyck-Jones, Jacqueline

AU - Ewenstein, Bruce

AU - Abbuehl, Brigitt

PY - 2012/6

Y1 - 2012/6

N2 - We report a prospective trial of 55 previously untreated patients (PUPs) and minimally treated patients (MTPs) with severe/moderately severe haemophilia A (baseline factor VIII [FVIII] ≤2%) treated with a single FVIII replacement product. It was the objective of this study to evaluate the immunogenicity, efficacy, and safety of rAHF-PFM (Advate ®). On-demand or prophylactic treatment regimens were determined at the discretion of the investigator. rAHF-PFM was also permitted for peri-operative management. There were 633 bleeding episodes (BEs), including 517 treated, and 466 rated for efficacy. Haemostatic efficacy was considered excellent/good in 93% of 466 rated treatments. Of 517 treated BEs, 463/517 (90%) were managed with one (356/517 [69%]) or two infusions (107/517 [21%]). There were 27 surgeries. Intraoper-ative (n=22) and postoperative (n=25) haemostatic efficacies were considered excellent or good in 100% of rated surgeries. Related serious adverse events (SAEs) were inhibitor development in 16/55 (29.1%) subjects who received at least one infusion of rAHF-PFM. Non-serious, related adverse events (AEs) were few in number (14 in eight subjects). The odds ratio (OR [95% Confidence Interval, CI]) of developing inhibitors was significantly higher in subjects with a family history of inhibitor (4.95 [1.29-19.06]), non-Caucasian ethnicity (4.18, [1.18-14.82]), and intensive treatment at high dose (4.5 [1.05-19.25]) within ≤20 exposure days (EDs). In conclusion, rAHF-PFM was safe and effective for the management and perioperative coverage of PUPs/ MTPs with severe/moderately severe haemophilia A. This report supports previous findings from studies in which family history of inhibitor, non-Caucasian ethnicity, and high intensity treatment were associated with high risk of inhibitor development.

AB - We report a prospective trial of 55 previously untreated patients (PUPs) and minimally treated patients (MTPs) with severe/moderately severe haemophilia A (baseline factor VIII [FVIII] ≤2%) treated with a single FVIII replacement product. It was the objective of this study to evaluate the immunogenicity, efficacy, and safety of rAHF-PFM (Advate ®). On-demand or prophylactic treatment regimens were determined at the discretion of the investigator. rAHF-PFM was also permitted for peri-operative management. There were 633 bleeding episodes (BEs), including 517 treated, and 466 rated for efficacy. Haemostatic efficacy was considered excellent/good in 93% of 466 rated treatments. Of 517 treated BEs, 463/517 (90%) were managed with one (356/517 [69%]) or two infusions (107/517 [21%]). There were 27 surgeries. Intraoper-ative (n=22) and postoperative (n=25) haemostatic efficacies were considered excellent or good in 100% of rated surgeries. Related serious adverse events (SAEs) were inhibitor development in 16/55 (29.1%) subjects who received at least one infusion of rAHF-PFM. Non-serious, related adverse events (AEs) were few in number (14 in eight subjects). The odds ratio (OR [95% Confidence Interval, CI]) of developing inhibitors was significantly higher in subjects with a family history of inhibitor (4.95 [1.29-19.06]), non-Caucasian ethnicity (4.18, [1.18-14.82]), and intensive treatment at high dose (4.5 [1.05-19.25]) within ≤20 exposure days (EDs). In conclusion, rAHF-PFM was safe and effective for the management and perioperative coverage of PUPs/ MTPs with severe/moderately severe haemophilia A. This report supports previous findings from studies in which family history of inhibitor, non-Caucasian ethnicity, and high intensity treatment were associated with high risk of inhibitor development.

KW - Factor viii

KW - Factor viii inhibitor

KW - Haemophilia a

KW - Minimally treated patients

KW - Paediatric

KW - Previously untreated patients

UR - http://www.scopus.com/inward/record.url?scp=84861735411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861735411&partnerID=8YFLogxK

U2 - 10.1160/TH11-09-0642

DO - 10.1160/TH11-09-0642

M3 - Article

C2 - 22476554

AN - SCOPUS:84861735411

VL - 107

SP - 1072

EP - 1082

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 6

ER -